We are live on ! Find out more
PMVP icon

PMV Pharmaceuticals
PMVP

51 hedge funds and large institutions have $1.09B invested in PMV Pharmaceuticals in 2020 Q3 according to their latest regulatory filings, with 51 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

72.59% more ownership

Funds ownership: 0% → 72.59% (+73%)

Holders
51
Holders Change
+51
Holders Change %
–
% of All Funds
1.03%
Holding in Top 10
3
Holding in Top 10 Change
+3
Holding in Top 10 Change %
% of All Funds
0.06%
New
51
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
O
OrbiMed
New York
+$270M
2
IVM
InterWest Venture Management
California
+$238M
3
Viking Global Investors
Viking Global Investors
Connecticut
+$97.2M
4
BC
Boxer Capital
California
+$83.5M
5
ACA
Avoro Capital Advisors
New York
+$68.1M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
Jennison Associates
26
Jennison Associates
New York
$5.33M +$5.52M +150,000 New
LGM
27
Logos Global Management
California
$5.33M +$5.52M +150,000 New
OMC
28
Old Mission Capital
Illinois
$1.83M +$1.9M +51,700 New
DM
29
Deerfield Management
New York
$1.77M +$1.84M +50,000 New
EC
30
EcoR1 Capital
California
$1.77M +$1.84M +50,000 New
Holocene Advisors
31
Holocene Advisors
New York
$1.77M +$1.84M +50,000 New
Legal & General Group
32
Legal & General Group
United Kingdom
$1.73M +$1.7M +46,300 New
Geode Capital Management
33
Geode Capital Management
Massachusetts
$1.17M +$1.21M +33,000 New
Jane Street
34
Jane Street
New York
$1.11M +$1.15M +31,349 New
PCM
35
Pinz Capital Management
New York
$987K +$1.02M +27,814 New
ACM
36
Asymmetry Capital Management
California
$884K +$916K +24,892 New
Squarepoint
37
Squarepoint
New York
$787K +$815K +22,156 New
Vanguard Group
38
Vanguard Group
Pennsylvania
$710K +$736K +20,000 New
Northern Trust
39
Northern Trust
Illinois
$567K +$588K +15,978 New
Citadel Advisors
40
Citadel Advisors
Florida
$475K +$492K +13,375 New
AGM
41
Alpine Global Management
New York
$415K +$431K +11,701 New
PPA
42
Parametric Portfolio Associates
Washington
$382K +$396K +10,763 New
JP Morgan Chase
43
JP Morgan Chase
New York
$380K +$368K +10,000 New
LCM
44
Laurion Capital Management
New York
$355K +$368K +10,000 New
Morgan Stanley
45
Morgan Stanley
New York
$245K +$254K +6,900 New
PHK
46
Point72 Hong Kong
Hong Kong
$223K +$232K +6,291 New
MS
47
Maven Securities
Jersey
$200K +$184K +5,000 New
SCM
48
Sio Capital Management
New York
$36K +$36.8K +1,000 New
UBS Group
49
UBS Group
Switzerland
$20K +$21K +571 New
Bank of America
50
Bank of America
North Carolina
$11K +$11K +300 New
1
2
3

PMVP Hedge Fund Activity: Q3 2020 in Review

51 of the 4,957 institutional investors tracked by Wall St. Rank reported a position in PMV Pharmaceuticals (PMVP) for Q3 2020, worth a combined $1.09B.

Buyers outnumbered sellers: 51 funds opened new PMVP positions and 0 closed out — a net gain of 51 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was OrbiMed, opening a new position worth an estimated $270M.

  • 51 institutional investors held PMV Pharmaceuticals (PMVP) as of Q3 2020, up from 0 in Q2 2020.
  • Funds reported $1.09B of PMV Pharmaceuticals stock for Q3 2020.
  • 51 funds opened new PMV Pharmaceuticals positions in Q3 2020 and 0 closed out, a net change of +51 holders.
  • The largest PMV Pharmaceuticals buyer in Q3 2020 was OrbiMed, an estimated $270M added.

Based on aggregated 13F filings for Q3 2020.